×
News Home

Should You Add Caribou Biosciences Inc (CRBU) Stock to Your Portfolio Tuesday?

Tuesday, October 04, 2022 12:15 PM | InvestorsObserver Analysts
Should You Add Caribou Biosciences Inc (CRBU) Stock to Your Portfolio Tuesday?

Caribou Biosciences Inc (CRBU) is around the top of the Healthcare sector according to InvestorsObserver. CRBU received an overall rating of 47, which means that it scores higher than 47% of stocks. Additionally, Caribou Biosciences Inc scored a 90 in the Healthcare sector, ranking it higher than 90% of stocks in that sector.

Overall Score - 47
CRBU has an Overall Score of 47. Find out what this means to you and get the rest of the rankings on CRBU!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. *Investors Observer* allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 47 would rank higher than 47 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Caribou Biosciences Inc Stock Today?

Caribou Biosciences Inc (CRBU) stock is trading at $11.18 as of 12:15 PM on Tuesday, Oct 4, a rise of $0.58, or 5.47% from the previous closing price of $10.60. The stock has traded between $11.02 and $11.52 so far today. Volume today is below average. So far 151,473 shares have traded compared to average volume of 871,230 shares. Click Here to get the full Stock Report for Caribou Biosciences Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App